Believing in biotech

03.10.2012

Believing in Biotech

Published on 03 October 2012

EuropaBio's Secretary General Nathalie Moll and Healthcare Director Miram Gargesi give an overview of the importance of biotechnology for Europe… 

 

It is estimated by the Organisation for Economic Co-operation and Development (OECD) that by 2015 health­care biotechnology knowledge will be used in the development of all new pharmaceutical products. As it stands, more than 350 million patients1have already benefited from approved medicines manufactured through biotechnology to treat or prevent a multitude of infections and diseases, such as cancers, heart attacks, stroke, multiple sclerosis, leukaemia, diabetes and rare diseases. The healthcare biotechnology industry in the EU is contributing to advancing patients' rights of access to the most innovative and modern medicines available. It has the potential to have a tremendous impact on meeting the needs of patients and their families. The industry not only encompasses medicines and diagnostics that are manufactured using a biotechnological process, but also novel biotech-based therapies, such as gene and cell therapies and tissue-engineered products.  The full article is available here